PETALING JAYA: UMediC Group Bhd
expects its expanded manufacturing capabilities and growing exposure to specialised healthcare segments to support its next phase of growth after fourth-quarter revenue jumped 52.1% year-on-year to RM18.7mil.
The medical device marketing, distribution and manufacturing group said the stronger quarterly performance for the period ended July 31, 2026 was mainly driven by higher contributions from its marketing and distribution segment.
Gross profit stood at RM7.1mil, while profit before tax came in at RM3mil and net profit at RM1.9mil.
For the full financial year, UMediC’s revenue rose 20.8% to RM58.7mil from RM48.6mil a year earlier.
Gross profit increased 11.7% to RM25mil, while profit before tax and profit after tax amounted to RM10.1mil and RM8.1mil, respectively.
Executive director and chief executive officer Lim Taw Seong said the group continues to build on investments made over the past few years as it strengthens its manufacturing, distribution and specialised healthcare capabilities.
“Our expanded manufacturing footprint provides the capacity to support the growing demand for our proprietary medical devices and consumables, while enabling us to pursue new growth opportunities in both the domestic and international markets,” he said in a statement.
UMediC is also expanding its presence in higher-value healthcare segments, particularly neurology, through strategic partnerships with private hospital groups and the introduction of Vagus Nerve Stimulation therapy.
Lim said these initiatives have strengthened the group’s position in an increasingly specialised healthcare field.
